DrugPatentWatch Database Preview

Details for Patent: 7,731,989

« Back to Dashboard

Which drugs does patent 7,731,989 protect, and when does it expire?

Patent 7,731,989 protects GRALISE and is included in one NDA.

This patent has twenty-four patent family members in nine countries.

Summary for Patent: 7,731,989

Title:	Gastric retained gabapentin dosage form
Abstract:	A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Inventor(s):	Berner; Bret (El Granada, CA), Hou; Sui Yuen Eddie (Foster City, CA), Gusler; Gloria M. (Cupertino, CA)
Assignee:	Depomed, Inc. (Menlo Park, CA)
Application Number:	12/239,591
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,731,989
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,731,989
Patent Claim Types: see list of patent claims	Compound; Dosage form; Formulation;

Drugs Protected by US Patent 7,731,989

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Assertio	GRALISE	gabapentin	TABLET;ORAL	022544-001	Jan 28, 2011	BX	RX	Yes	Yes			Y
Assertio	GRALISE	gabapentin	TABLET;ORAL	022544-002	Jan 28, 2011	BX	RX	Yes	Yes			Y

International Family Members for US Patent 7,731,989

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002348828
Australia	2005267738
Australia	2006332690
Canada	2464322